Formycon revenue triples in H1 2026 on biosimilar growth

German biotech company Formycon said on Friday its revenue more than tripled in the first half of 2026, fueled by robust demand for its biosimilar products.

The company, which develops and markets biosimilars—biological medicines highly similar to already approved reference products—reported that revenue rose to €180 million in H1 2026 from €60 million in the same period a year earlier. Formycon attributed the growth to increased sales of its key biosimilar assets, including its flagship ophthalmology treatment.

Formycon’s biosimilar portfolio targets chronic and severe diseases, with a focus on immunology, ophthalmology and oncology. The company’s lead product, FYB201, a biosimilar to Eylea (aflibercept), has been a significant contributor to revenue growth, supported by expanding market adoption in Europe and other regions.

The company also highlighted ongoing regulatory progress, including submissions for additional biosimilar candidates and partnerships with global distributors to broaden market access. Formycon reiterated its commitment to scaling production and advancing its late-stage pipeline to sustain momentum.

Analysts noted that the strong revenue performance reflects broader industry trends favoring cost-effective biosimilar alternatives to high-priced biologics. The sector has seen accelerated adoption amid healthcare cost pressures and patent expirations on blockbuster drugs.

Formycon’s shares, listed on the Frankfurt Stock Exchange under the ticker FYB, have gained roughly 15% since the start of 2026, outperforming the broader biotech index in Europe.